JP2021502104A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021502104A5 JP2021502104A5 JP2020526175A JP2020526175A JP2021502104A5 JP 2021502104 A5 JP2021502104 A5 JP 2021502104A5 JP 2020526175 A JP2020526175 A JP 2020526175A JP 2020526175 A JP2020526175 A JP 2020526175A JP 2021502104 A5 JP2021502104 A5 JP 2021502104A5
- Authority
- JP
- Japan
- Prior art keywords
- heavy chain
- cancer
- domain antibody
- single variable
- variable heavy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023111710A JP2023126951A (ja) | 2017-11-13 | 2023-07-06 | Ｃｄ１３７に結合するシングルドメイン抗体 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1718734.5A GB201718734D0 (en) | 2017-11-13 | 2017-11-13 | Single domain antibodies that bind to CD137 |
| GB1718734.5 | 2017-11-13 | ||
| GB1718735.2 | 2017-11-13 | ||
| GBGB1718735.2A GB201718735D0 (en) | 2017-11-13 | 2017-11-13 | Bispecific molecules that bind to CD137 and PSMA |
| GBGB1808589.4A GB201808589D0 (en) | 2018-05-24 | 2018-05-24 | Single domain antibodies that bind CD137 |
| GB1808589.4 | 2018-05-24 | ||
| PCT/GB2018/053279 WO2019092451A1 (en) | 2017-11-13 | 2018-11-13 | Single Domain Antibodies that Bind to CD137 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023111710A Division JP2023126951A (ja) | 2017-11-13 | 2023-07-06 | Ｃｄ１３７に結合するシングルドメイン抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021502104A JP2021502104A (ja) | 2021-01-28 |
| JP2021502104A5 true JP2021502104A5 (enExample) | 2021-12-23 |
| JP7312168B2 JP7312168B2 (ja) | 2023-07-20 |
Family
ID=64457031
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020526175A Active JP7312168B2 (ja) | 2017-11-13 | 2018-11-13 | Ｃｄ１３７に結合するシングルドメイン抗体 |
| JP2020526245A Ceased JP2021502810A (ja) | 2017-11-13 | 2018-11-13 | Ｃｄ１３７およびｐｓｍａに結合する分子 |
| JP2023111710A Pending JP2023126951A (ja) | 2017-11-13 | 2023-07-06 | Ｃｄ１３７に結合するシングルドメイン抗体 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020526245A Ceased JP2021502810A (ja) | 2017-11-13 | 2018-11-13 | Ｃｄ１３７およびｐｓｍａに結合する分子 |
| JP2023111710A Pending JP2023126951A (ja) | 2017-11-13 | 2023-07-06 | Ｃｄ１３７に結合するシングルドメイン抗体 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20200362051A1 (enExample) |
| EP (2) | EP3710477A1 (enExample) |
| JP (3) | JP7312168B2 (enExample) |
| KR (2) | KR20200083574A (enExample) |
| CN (4) | CN111683968B (enExample) |
| AU (2) | AU2018363291A1 (enExample) |
| CA (2) | CA3082297A1 (enExample) |
| IL (2) | IL274370A (enExample) |
| SG (2) | SG11202003978UA (enExample) |
| WO (2) | WO2019092451A1 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11236174B2 (en) | 2016-01-12 | 2022-02-01 | Crescendo Biologics Limited | Therapeutic molecules |
| GB201607968D0 (en) | 2016-05-06 | 2016-06-22 | Crescendo Biolog Ltd | Chimeric antigen receptor |
| EP3565842A1 (en) | 2017-01-06 | 2019-11-13 | Crescendo Biologics Limited | Single domain antibodies to programmed cell death (pd-1) |
| GB201711068D0 (en) * | 2017-07-10 | 2017-08-23 | Crescendo Biologics Ltd | Therapeutic molecules binding PSMA |
| JP7312168B2 (ja) * | 2017-11-13 | 2023-07-20 | クレッシェンド、バイオロジックス、リミテッド | Ｃｄ１３７に結合するシングルドメイン抗体 |
| GB201802573D0 (en) | 2018-02-16 | 2018-04-04 | Crescendo Biologics Ltd | Therapeutic molecules that bind to LAG3 |
| JP2020132572A (ja) * | 2019-02-20 | 2020-08-31 | 旭化成株式会社 | シラノール組成物、硬化物及び製造方法 |
| KR20220008839A (ko) * | 2019-05-15 | 2022-01-21 | 크레센도 바이오로직스 리미티드 | 결합 분자 |
| MY207446A (en) | 2019-08-12 | 2025-02-27 | Abl Bio Inc | Anti-claudin 18.2 and anti-4-1bb bispecific antibodies and uses thereof |
| JP7432716B2 (ja) * | 2019-11-13 | 2024-02-16 | 合肥瀚科邁博生物技術有限公司 | ヒト４－１ｂｂに結合可能な分子及びその応用 |
| PH12022551211A1 (en) * | 2019-11-18 | 2023-10-02 | Janssen Biotech Inc | Anti-cd79 chimeric antigen receptors, car-t cells, and uses thereof |
| JP2023531042A (ja) * | 2020-06-30 | 2023-07-20 | 諾納生物（蘇州）有限公司 | ４－１ｂｂ結合タンパク質及びその用途 |
| EP4214233A1 (en) | 2020-09-16 | 2023-07-26 | Amgen Inc. | Methods for administering therapeutic doses of bispecific t-cell engaging molecules for the treatment of cancer |
| CN114195894B (zh) * | 2020-09-17 | 2025-02-25 | 普米斯生物技术(珠海)有限公司 | 一种靶向4-1bb的抗体及其应用 |
| EP4341294A1 (en) * | 2021-05-21 | 2024-03-27 | BeiGene Switzerland GmbH | Anti-gpc3 and anti-cd137 multispecific antibodies and methods of use |
| TW202306984A (zh) * | 2021-05-21 | 2023-02-16 | 英屬開曼群島商百濟神州有限公司 | 抗ｃｄ１３７抗體及使用方法 |
| CN113621065B (zh) * | 2021-08-30 | 2023-08-01 | 武汉海沙百得生物技术有限公司 | 靶向4-1bb的全人源抗体及其制备方法和应用 |
| IL311144A (en) * | 2021-08-31 | 2024-04-01 | Lanova Medicines Ltd | Anti-1-4BB Nanobodies |
| WO2024040194A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| JP2025531938A (ja) * | 2022-09-22 | 2025-09-25 | アブリンク バイオテック カンパニー リミテッド | 抗４－１ｂｂナノボディ、その製造及び使用 |
| KR20250110345A (ko) * | 2022-11-21 | 2025-07-18 | 비원 메디슨즈 아이 게엠베하 | 항-cd137 항체 및 사용 방법 |
| CN121666232A (zh) | 2023-05-31 | 2026-03-13 | 开普斯坦治疗公司 | 脂质纳米颗粒制剂和组合物 |
| JP2025022410A (ja) | 2023-08-03 | 2025-02-14 | ルネサスエレクトロニクス株式会社 | 半導体装置およびその製造方法 |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| WO2025076127A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025179294A2 (en) | 2024-02-22 | 2025-08-28 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025214249A1 (en) * | 2024-04-12 | 2025-10-16 | Suzhou Biomissile Pharmaceuticals Co., Ltd. | Anti-4-bb single domain antibodies, bispecific antibodies and uses thereof |
| CN118629502A (zh) * | 2024-06-19 | 2024-09-10 | 中山百灵生物技术股份有限公司 | 基于数据处理的核苷酸序列实验预测优化系统 |
Family Cites Families (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0115256D0 (en) | 2001-06-21 | 2001-08-15 | Babraham Inst | Mouse light chain locus |
| ES2559002T3 (es) | 2001-10-23 | 2016-02-10 | Psma Development Company, L.L.C. | Anticuerpos contra PSMA |
| GB2398784B (en) | 2003-02-26 | 2005-07-27 | Babraham Inst | Removal and modification of the immunoglobulin constant region gene cluster of a non-human mammal |
| GB0400440D0 (en) | 2004-01-09 | 2004-02-11 | Isis Innovation | Receptor modulators |
| CA2569509C (en) * | 2004-06-03 | 2014-08-12 | Novimmune S.A. | Anti-cd3 antibodies and methods of use thereof |
| GB0521621D0 (en) * | 2005-10-24 | 2005-11-30 | Domantis Ltd | Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases |
| WO2006089230A2 (en) | 2005-02-18 | 2006-08-24 | Medarex, Inc. | Human monoclonal antibodies to prostate specific membrane antigen (psma) |
| CA2616859C (en) | 2005-08-03 | 2015-04-14 | Fraunhofer Usa, Inc. | Compositions and methods for production of immunoglobulins |
| EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| CA2718705A1 (en) | 2008-03-17 | 2009-09-24 | Allergan, Inc. | S1p3 receptor inhibitors for treating inflammation |
| US20100122358A1 (en) | 2008-06-06 | 2010-05-13 | Crescendo Biologics Limited | H-Chain-only antibodies |
| AU2009270793A1 (en) * | 2008-07-18 | 2010-01-21 | Oragenics, Inc. | Compositions for the detection and treatment of colorectal cancer |
| BRPI0919377A2 (pt) | 2008-09-26 | 2016-09-27 | Dana Farber Cancer Inst Inc | anticorpo isolado ou um fragmento ligante de antígeno do memso, ácido nucleico isolado, vetor, célula hospedeira, composição farmacêutica, método de produzir o referido anticorpo ou fragmento, uso dos mesmos, e composição compreendendo o referido anticorpo ou fragmento |
| US9120855B2 (en) * | 2010-02-10 | 2015-09-01 | Novartis Ag | Biologic compounds directed against death receptor 5 |
| US20130202623A1 (en) | 2010-02-16 | 2013-08-08 | Nicolas Chomont | Pd-1 modulation and uses thereof for modulating hiv replication |
| TW201134488A (en) | 2010-03-11 | 2011-10-16 | Ucb Pharma Sa | PD-1 antibodies |
| JP2014501515A (ja) | 2010-12-01 | 2014-01-23 | グラクソ グループ リミテッド | 改良された抗血清アルブミン結合単一可変ドメイン |
| WO2013045916A1 (en) | 2011-09-26 | 2013-04-04 | Kymab Limited | Chimaeric surrogate light chains (slc) comprising human vpreb |
| MX2014010183A (es) | 2012-02-22 | 2015-03-20 | Univ Pennsylvania | Composiciones y metodos para generar una poblacion persistente de celulas t utiles para el tratamiento de cancer. |
| WO2013167883A1 (en) | 2012-05-07 | 2013-11-14 | The University Court Of The University Of Aberdeen | Single domain binding molecule |
| ES2715279T3 (es) * | 2012-05-24 | 2019-06-03 | Vib Vzw | Dominios variables individuales inmunoglobulínicos anti-receptor de manosa de macrófagos para elegir como diana y obtener imágenes in vivo de macrófagos asociados a tumores |
| CN103087171B (zh) | 2012-12-24 | 2015-01-14 | 中国人民解放军第四军医大学 | 一种用于前列腺癌早期诊断和治疗的抗psma/fitc双特异性抗体及其制备方法 |
| WO2014141192A1 (en) | 2013-03-15 | 2014-09-18 | Erasmus University Medical Center | Generation of heavy chain-only antibodies |
| CN103333249A (zh) | 2013-06-14 | 2013-10-02 | 广州康合生物科技有限公司 | 一种抗前列腺特异性膜抗原（psma）的单克隆抗体及其应用 |
| EA029901B1 (ru) | 2013-09-04 | 2018-05-31 | Бристол-Майерс Сквибб Компани | Соединения для применения в качестве иммуномодуляторов |
| ES2716685T3 (es) | 2014-01-24 | 2019-06-14 | Dana Farber Cancer Inst Inc | Moléculas de anticuerpo para PD-1 y usos de las mismas |
| KR20160106762A (ko) | 2014-01-28 | 2016-09-12 | 브리스톨-마이어스 스큅 컴퍼니 | 혈액 악성종양을 치료하기 위한 항-lag-3 항체 |
| KR20150089702A (ko) | 2014-01-28 | 2015-08-05 | 제일모직주식회사 | 신규 화합물, 신규 폴리머, 이를 포함하는 착색제, 이를 포함하는 감광성 수지 조성물 및 컬러필터 |
| JP2017513818A (ja) | 2014-03-15 | 2017-06-01 | ノバルティス アーゲー | キメラ抗原受容体を使用する癌の処置 |
| TWI701042B (zh) | 2014-03-19 | 2020-08-11 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
| ES2900898T3 (es) | 2014-04-07 | 2022-03-18 | Chugai Pharmaceutical Co Ltd | Anticuerpos biespecíficos inmunoactivadores |
| MA39378B2 (fr) | 2014-04-25 | 2021-02-26 | Pf Medicament | Anticorps igf-1r et son utilisation comme véhicule d'adressage pour le traitement du cancer |
| US10092645B2 (en) * | 2014-06-17 | 2018-10-09 | Medimmune Limited | Methods of treatment with antagonists against PD-1 and PD-L1 in combination with radiation therapy |
| TWI693232B (zh) | 2014-06-26 | 2020-05-11 | 美商宏觀基因股份有限公司 | 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法 |
| US9982053B2 (en) | 2014-08-05 | 2018-05-29 | MabQuest, SA | Immunological reagents |
| AU2015301460B2 (en) | 2014-08-14 | 2021-04-08 | Novartis Ag | Treatment of cancer using GFR alpha-4 chimeric antigen receptor |
| US11547099B2 (en) | 2014-10-22 | 2023-01-10 | Crescendo Biologies Limited | Transgenic mice |
| WO2016073760A1 (en) | 2014-11-05 | 2016-05-12 | The Regents Of The University Of California | Methods for stratifying non-responders to therapies that block pd1/pdl1 axis |
| CA3175979A1 (en) | 2014-12-22 | 2016-06-30 | Pd-1 Acquisition Group, Llc | Anti-pd-1 antibodies |
| AU2016258977C1 (en) | 2015-05-04 | 2022-07-14 | Pieris Pharmaceuticals Gmbh | Anti-cancer fusion polypeptide |
| AU2016262845B2 (en) * | 2015-05-18 | 2020-07-23 | Pieris Pharmaceuticals Gmbh | Anti-cancer fusion polypeptide |
| CN105061597B (zh) | 2015-06-09 | 2016-04-27 | 北京东方百泰生物科技有限公司 | 一种抗pd-1的单克隆抗体及其获得方法 |
| HUE055207T2 (hu) | 2015-07-30 | 2021-11-29 | Macrogenics Inc | PD-1 és LAG-3 kötõ molekulák és eljárások azok alkalmazására |
| CN106397592A (zh) | 2015-07-31 | 2017-02-15 | 苏州康宁杰瑞生物科技有限公司 | 针对程序性死亡配体(pd-l1)的单域抗体及其衍生蛋白 |
| CN105384825B (zh) | 2015-08-11 | 2018-06-01 | 南京传奇生物科技有限公司 | 一种基于单域抗体的双特异性嵌合抗原受体及其应用 |
| AU2016334623A1 (en) * | 2015-10-07 | 2018-02-15 | F. Hoffmann-La Roche Ag | Bispecific antibodies with tetravalency for a costimulatory TNF receptor |
| SG11201804178YA (en) | 2015-11-18 | 2018-06-28 | Merck Sharp & Dohme | Pd1 and/or lag3 binders |
| MX2018008308A (es) | 2016-01-11 | 2019-05-15 | Inhibrx Inc | Proteinas de fusion de union a 41bb multivalentes y multiespecificas. |
| US11236174B2 (en) | 2016-01-12 | 2022-02-01 | Crescendo Biologics Limited | Therapeutic molecules |
| CN105968205B (zh) | 2016-02-03 | 2019-04-26 | 中国人民解放军第三军医大学第三附属医院 | 一种抗前列腺特异性膜抗原的纳米抗体 |
| CN105968203A (zh) | 2016-02-03 | 2016-09-28 | 南昌大学 | 一种抗前列腺特异性膜抗原胞外区的单域重链抗体 |
| CN105968204B (zh) | 2016-02-03 | 2020-01-21 | 中国人民解放军第三军医大学第一附属医院 | 一种抗前列腺特异性膜抗原的单域重链抗体 |
| RU2018139339A (ru) | 2016-04-22 | 2020-05-22 | Эллигейтор Биосайенс Аб | Новые биспецифические полипептиды против cd137 |
| GB201607968D0 (en) | 2016-05-06 | 2016-06-22 | Crescendo Biolog Ltd | Chimeric antigen receptor |
| CA3024723A1 (en) | 2016-05-20 | 2017-11-23 | Robert B. Dubridge | Single domain serum albumin binding protein |
| SG11201810591VA (en) | 2016-05-27 | 2018-12-28 | Abbvie Biotherapeutics Inc | Bispecific binding proteins binding an immunomodulatory protein and a tumor antigen |
| IL310340A (en) | 2016-12-07 | 2024-03-01 | Ablynx Nv | Improved serum albumin binding immunoglobulin single variable domains |
| CN107674122A (zh) | 2016-12-28 | 2018-02-09 | 天津天锐生物科技有限公司 | 一种识别人血清白蛋白的单域抗体 |
| EP3565842A1 (en) | 2017-01-06 | 2019-11-13 | Crescendo Biologics Limited | Single domain antibodies to programmed cell death (pd-1) |
| CA3052291A1 (en) | 2017-02-09 | 2018-08-16 | Memorial Sloan Kettering Cancer Center | Anti-kir3dl1 antibodies |
| WO2018224439A1 (en) | 2017-06-05 | 2018-12-13 | Numab Innovation Ag | Novel anti-hsa antibodies |
| EP3425763B1 (en) | 2017-07-03 | 2020-11-18 | France Brevets | Coupling interface and method of operation |
| TW202542197A (zh) | 2017-07-06 | 2025-11-01 | 荷蘭商米樂斯股份有限公司 | 藉由細胞表現之調控生物活性的抗體 |
| GB201711068D0 (en) | 2017-07-10 | 2017-08-23 | Crescendo Biologics Ltd | Therapeutic molecules binding PSMA |
| EP3470426A1 (en) | 2017-10-10 | 2019-04-17 | Numab Therapeutics AG | Multispecific antibody |
| PE20200849A1 (es) * | 2017-10-10 | 2020-08-20 | Numab Therapeutics AG | Anticuerpo multiespecifico |
| JP7312168B2 (ja) | 2017-11-13 | 2023-07-20 | クレッシェンド、バイオロジックス、リミテッド | Ｃｄ１３７に結合するシングルドメイン抗体 |
| GB201802573D0 (en) | 2018-02-16 | 2018-04-04 | Crescendo Biologics Ltd | Therapeutic molecules that bind to LAG3 |
| GB201818460D0 (en) | 2018-11-13 | 2018-12-26 | Crescendo Biologics Ltd | Single domain antibodies that bind human serum albumin |
| KR20220008839A (ko) | 2019-05-15 | 2022-01-21 | 크레센도 바이오로직스 리미티드 | 결합 분자 |
-
2018
- 2018-11-13 JP JP2020526175A patent/JP7312168B2/ja active Active
- 2018-11-13 CA CA3082297A patent/CA3082297A1/en active Pending
- 2018-11-13 US US16/763,063 patent/US20200362051A1/en not_active Abandoned
- 2018-11-13 CN CN201880086045.1A patent/CN111683968B/zh active Active
- 2018-11-13 SG SG11202003978UA patent/SG11202003978UA/en unknown
- 2018-11-13 WO PCT/GB2018/053279 patent/WO2019092451A1/en not_active Ceased
- 2018-11-13 AU AU2018363291A patent/AU2018363291A1/en not_active Abandoned
- 2018-11-13 US US16/763,059 patent/US12077595B2/en active Active
- 2018-11-13 CN CN201880085847.0A patent/CN111699197B/zh active Active
- 2018-11-13 CN CN202411099964.6A patent/CN118955716A/zh active Pending
- 2018-11-13 EP EP18808057.6A patent/EP3710477A1/en active Pending
- 2018-11-13 AU AU2018363292A patent/AU2018363292A1/en not_active Abandoned
- 2018-11-13 KR KR1020207016092A patent/KR20200083574A/ko not_active Ceased
- 2018-11-13 SG SG11202003912RA patent/SG11202003912RA/en unknown
- 2018-11-13 EP EP18808058.4A patent/EP3710478A1/en active Pending
- 2018-11-13 CA CA3082321A patent/CA3082321A1/en active Pending
- 2018-11-13 KR KR1020207016093A patent/KR20200080304A/ko not_active Ceased
- 2018-11-13 WO PCT/GB2018/053280 patent/WO2019092452A1/en not_active Ceased
- 2018-11-13 CN CN202410837001.5A patent/CN118667027A/zh active Pending
- 2018-11-13 JP JP2020526245A patent/JP2021502810A/ja not_active Ceased
-
2020
- 2020-04-30 IL IL274370A patent/IL274370A/en unknown
- 2020-04-30 IL IL274371A patent/IL274371A/en unknown
-
2023
- 2023-07-06 JP JP2023111710A patent/JP2023126951A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021502104A5 (enExample) | ||
| JP2020503870A5 (enExample) | ||
| TWI821474B (zh) | Ｃｄ３抗體及其藥物用途 | |
| JP2020058354A (ja) | 異常細胞を標的とする多重特異性結合分子 | |
| JP2021502810A5 (enExample) | ||
| JP2021102633A5 (enExample) | ||
| JP2020515235A5 (enExample) | ||
| CN112969476B (zh) | 多特异性蛋白分子 | |
| HRP20190756T1 (hr) | Cd3-vezujuće molekule sposobne za vezanje za humani i nehumani cd3 | |
| JP2015527070A5 (enExample) | ||
| WO2022135536A1 (zh) | Cd3人源化抗体及其应用 | |
| JPWO2020135201A5 (enExample) | ||
| JP2016521692A5 (enExample) | ||
| JPWO2017020812A5 (enExample) | ||
| JP2020534012A5 (enExample) | ||
| JPWO2019191120A5 (enExample) | ||
| CN115461373A (zh) | 密蛋白18.2的抗体及其用途 | |
| JP2019505545A5 (enExample) | ||
| CN114853897B (zh) | 抗cd19/cd22/cd3三特异性抗体及用途 | |
| JPWO2023078113A5 (enExample) | ||
| US20260055201A1 (en) | Bispecific antibody and use thereof | |
| CN114763387A (zh) | 一种基于结构优化蛋白活性的三特异性抗体制备方法 | |
| WO2023186100A1 (zh) | 抗ror1的抗体及其用途 | |
| TW202321311A (zh) | 與scFv等之連接子結合的抗體 | |
| CN117586410A (zh) | 一种结合TNFR2和Claudin18.2的双特异性抗体 |